IDXX

IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group; Water; Livestock, Poultry, and Dairy; and Other. The Companion Animal Group segment refers to diagnostic and information technology-based products and services for the veterinary market. The Water segment includes water quality products for testing of certain microbiological water contaminants. The Livestock, Poultry, and Dairy segment involves diagnostic, health-monitoring, and food safety testing products for livestock and poultry health, and dairy products. The Other segment include products for the human point-of-care medical diagnostics market with the company\'s pharmaceutical product line and out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

IDEXX Laboratories, Inc. (IDXX) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.3 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.7 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 47.0
EV / EBITDA 33.6
Rev Growth YoY 9.9%
Gross Margin 62.7%
Price Return 3M 29.0%
Price Return 12M -1.3%
Catalyst Signal +0.18
Market Cap $55.5B
TTM Revenue $4.7B
Price / Sales 11.9
ROE 68.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C (2.3) C (2.2) B (3.2) B (3.2) C+ (2.7) C+ (2.7)
2026-11-09 C (2.2) C (2.3) B (3.2) B- (2.9) C+ (2.7) C+ (2.6)
2026-11-04 C (2.5) C (2.2) B (3.2) C+ (2.6) C+ (2.7) C+ (2.6)
2026-11-03 C+ (2.5) C (2.2) B- (3.1) C (2.5) B- (3.0) C+ (2.7)
2026-11-02 C+ (2.5) C (2.2) B- (3.1) C (2.5) D+ (1.8) C (2.4)
Page 1 of 10
…